State Street Corp Has $41.99 Million Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

State Street Corp increased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 703,843 shares of the specialty pharmaceutical company's stock after purchasing an additional 58,698 shares during the period. State Street Corp owned approximately 3.35% of ANI Pharmaceuticals worth $41,991,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System boosted its stake in ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company's stock valued at $490,000 after buying an additional 200 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of ANI Pharmaceuticals by 10.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 131,156 shares of the specialty pharmaceutical company's stock worth $8,352,000 after purchasing an additional 12,865 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in ANI Pharmaceuticals by 6.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 22,751 shares of the specialty pharmaceutical company's stock valued at $1,449,000 after purchasing an additional 1,474 shares during the last quarter. Legato Capital Management LLC boosted its position in ANI Pharmaceuticals by 62.8% in the second quarter. Legato Capital Management LLC now owns 7,440 shares of the specialty pharmaceutical company's stock valued at $474,000 after buying an additional 2,870 shares in the last quarter. Finally, Ridgewood Investments LLC bought a new stake in ANI Pharmaceuticals during the second quarter worth about $85,000. Institutional investors own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company's stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,231 shares of company stock valued at $2,434,286 over the last 90 days. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Trading Down 1.7 %

ANI Pharmaceuticals stock traded down $0.91 during midday trading on Friday, hitting $53.35. 1,066,257 shares of the stock were exchanged, compared to its average volume of 225,876. ANI Pharmaceuticals, Inc. has a 52 week low of $52.00 and a 52 week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.12 billion, a PE ratio of -97.00 and a beta of 0.73. The company has a fifty day simple moving average of $57.85 and a two-hundred day simple moving average of $60.02.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price objective for the company. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 18th. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.